Moriya Tsuji, MD, PhD

  • Professor of Medicine at CUMC
Profile Headshot

Profile Navigation

Overview

Academic Appointments

  • Professor of Medicine at CUMC

Languages

  • Japanese

Gender

  • Male

Credentials & Experience

Education & Training

  • MD, 1983 Medicine, The Jikei University School of Medicine
  • PhD, 1987 Immunology, University of Tokyo-Japan
  • Fellowship: 1990 New York University School of Medicine

Committees, Societies, Councils

  • 11/2015 - present
  • 06/2007 - present
    • Member, Faculty of 1000 Biology, Immunology Section
  • 1997 - present
    • International Society for Vaccines
  • 1996 - present
    • American Society of Tropical Medicine and Hygiene
  • 1993 - present
    • American Association for the Advancement of Science
  • 1993 - present
    • American Association of Immunologists
  • 09/2013
    • Member, International Scientific Committee, 7th International Symposium on CD1 and NKT Cells, Tours, France, September 2013.
  • 01/2008 - 12/2012
    • Panel Member, Vaccine Science Portfolio Advisory Council (VSPAC) of the PATH Malaria Vaccine Initiative (MVI), Bethesda, MD
  • 09/2010 - 08/2012
    • Panel Member, Malaria Vaccine Consultation Group (MVCG) of NIAID, NIH
  • 09/2011
    • Session Chair, 6th International Symposium on CD1 and NK T Cells, Chicago, IL, September 2011
  • 06/2011
    • Scientific Advisory Group member for the NIH/NIAID site visit to the International Center for Excellence in Malaria Research (ICEMR) in Cali, Colombia
  • 10/2009
    • Chairman, 1st Malaria Vaccine Workshop organized by Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan
  • 05/2008, 10/2008
    • Member, Technical Advisory Group (TAG) for malaria vaccine development, The PATH 06/2012
    • Malaria Vaccine Initiative (MVI), Bethesda, MD
  • 02/2008
    • Session Chair, Keystone Symposium - NK and NKT cell Biology, Keystone, Colorado, February 24-29
  • 11/1999
    • Scientific Co-Chairman, 48th Annual Meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC; Nov 28 - Dec 2
  • 08/1998
    • Scientific Co-Chairman, 9th International Congress of Parasitology, Chiba, Japan; August 24-28

Honors & Awards

2021 Fellow of American Society of Medicine and Hygiene (FASTMH)

04/2014 - 03/2015 Mizutani Foundation for Glycoscience Award

11/2009 - 10/2010 Gates Grand Challenges Explorations Round 3

04/1997 - 03/2002 NIH FIRST Award

09/1999 - 09/2003 NIH Independent Scientist Award

07/1996 - 06/1998 American Lung Association of New York Research Award

09/1993 - 08/1994 New York University Whitehead Presidential Award

01/1993 - 12/1993 American Cancer Society Institutional Award

04/1983 - 03/1987 Japan Scholarship Society Award

Research

Selected Publications

  • Borges-Fernandes LO, de Lima Moreira M, Pereira VHS, Pascoal-Xavier MA, Lopes Ribeiro Á, da Costa-Rocha IA, Lopes LR, Moreira GTC, Araújo MSDS, Teixeira-Carvalho A, Brito-de-Sousa JP, de Carvalho AL, Mourão MVA, Campos FA, Borges M, Carneiro M, Tsuji M, Martins-Filho OA, Coelho-Dos-Reis JGA, Peruhype-Magalhães V. MR1 blockade drives differential impact on integrative signatures based on circuits of circulating immune cells and soluble mediators in visceral leishmaniasis. Front Immunol. 2024 Aug 13;15:1373498.
  • Xu Y, Masuda K, Groso C, Hassan R, Zhou Z, Broderick K, Tsuji M, Tison C. Microfluidic Synthesis of Scalable Layer-by-Layer Multiple Antigen Nano-Delivery Platform for SARS-CoV-2 Vaccines. Vaccines (Basel). 2024 Mar 21;12(3):339.
  • Watson FN, Shears MJ, Kalata AC, Duncombe CJ, Seilie AM, Chavtur C, Conrad E, Cruz Talavera I, Raappana A, Sather DN, Chakravarty S, Sim BKL, Hoffman SL, Tsuji M, Murphy SC. Ultra-low volume intradermal administration of radiation-attenuated sporozoites with the glycolipid adjuvant 7DW8-5 completely protects mice against malaria. Sci Rep. 2024 Feb 4;14(1):2881.
  • de Almeida Marques DP, Andrade LAF, Reis EVS, Clarindo FA, Moraes TFS, Lourenço KL, De Barros WA, Costa NEM, Andrade LM, Lopes-Ribeiro Á, Coêlho Maciel MS, Corrêa-Dias LC, de Almeida IN, Arantes TS, Litwinski VCV, de Oliveira LC, Serafim MSM, Maltarollo VG, Guatimosim SC, Silva MM, Tsuji M, Ferreira RS, Barreto LV, Barbosa-Stancioli EF, da Fonseca FG, De Fátima Â, Coelho-Dos-Reis JGA. New anti-SARS-CoV-2 aminoadamantane compounds as antiviral candidates for the treatment of COVID-19. Virus Res. 2024 Feb;340:199291.
  • Watson FN, Shears MJ, Kalata AC, Duncombe CJ, Seilie AM, Chavtur C, Conrad E, Talavera IC, Raappana A, Sather DN, Chakravarty S, Sim BKL, Hoffman SL, Tsuji M, Murphy SC. 2023. Ultra-low volume intradermal administration of radiation-attenuated sporozoites with the glycolipid adjuvant 7DW8-5 completely protects mice against malaria. Res Sq. Aug 11:rs.3.rs-3243319.
  • Xu Y, Ferguson T, Masuda K, Siddiqui MA, Smith KP, Vest O, Brooks B, Zhou Z, Obliosca J, Kong XP, Jiang X, Yamashita M, Tsuji M, Tison C. 2023. Short Carbon Nanotube-Based Delivery of mRNA for HIV-1 Vaccines. Biomolecules. 13: 1088.
  • Lopes-Ribeiro Á, Oliveira PM, Retes HM, Barbosa-Stancioli EF, da Fonseca FG, Tsuji M, Coelho-Dos-Reis JGA. Surveillance of SARS-CoV-2 immunogenicity: loss of immunodominant HLA-A*02-restricted epitopes that activate CD8+ T cells. Front Immunol. 2023 Nov 3;14:1229712.
  • Tsuji M, Nair MS, Masuda K, Castagna C, Chong Z, Darling TL, Seehra K, Hwang Y, Ribeiro ÁL, Ferreira GM, Corredor L, Coelho-Dos-Reis JGA, Tsuji Y, Mori M, Boon ACM, Diamond MS, Huang Y, Ho DD. 2023. An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo. Nat Commun. 14: 3959.
  • Kalpana K, Yap S, Tsuji M, Kawamura A. Molecular Mechanism behind the Safe Immunostimulatory Effect of Withania somnifera. Biomolecules. 2023 May 12;13(5):828.
  • Pereira-Santos TA, da Rocha AS, Lopes-Ribeiro Á, Corrêa-Dias LC, Melo-Oliveira P, Reis EVS, da Fonseca FG, Barbosa-Stancioli EF, Tsuji M, Coelho-Dos-Reis JGA. Diversity of HLA-A2-Restricted and Immunodominant Epitope Repertoire of Human T-Lymphotropic Virus Type 1 (HTLV-1) Tax Protein: Novel Insights among N-Terminal, Central and C-Terminal Regions. Biomolecules. 2023 Mar 16;13(3):545.
  • Miyamura N, Suzuki K, Friedman RA, Floratos A, Kunisada Y, Masuda K, Lowy AM, Tsuji M, Sugahara KN. 2023. A pancreatic cancer mouse model with human immunity. bioRxiv. May 24:2023.05.24.542127.
  • Watson FN, Duncombe CJ, Kalata AC, Conrad E, Chakravarty S, Sim BKL, Hoffman SL, Tsuji M, Shears MJ, Murphy SC. Sex-Specific Differences in Cytokine Induction by the Glycolipid Adjuvant 7DW8-5 in Mice. Biomolecules. 2022 Dec 21;13(1):8.
  • Xu Y, Zhou Z, Brooks B, Ferguson T, Obliosca J, Huang J, Kaneko I, Iwanaga S, Yuda M, Tsuji Y, Zhang H, Luo CC, Jiang X, Kong XP, Tsuji M, Tison CK. 2022. Layer-by-Layer Delivery of Multiple Antigens Using Trimethyl Chitosan Nanoparticles as a Malaria Vaccine Candidate. Front Immunol. 13: 900080.
  • Mogus AT, Liu L, Jia M, Ajayi DT, Xu K, Kong R, Huang J, Yu J, Kwong PD, Mascola JR, Ho DD, Tsuji M, Chackerian B. 2020. Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide. Vaccines (Basel). 8: E765.
  • Huang J, Zhou J, Ghinnagow R, Seki T, Iketani S, Soulard D, Paczkowski P, Tsuji Y, MacKay S, Cruz LJ, Trottein F, Tsuji M. 2020. Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice. Front Immunol. 11: 2043.
  • Coelho-dos-Reis JGA, Funakoshi R, Huang J, Pereira FV, Iketani S, Tsuji M. 2020. Functional Human CD141+ Dendritic Cells in Human Immune System Mice. J. Infect. Dis. 221:201-213.
  • Shiratsuchi T, Rai U, Kaneko I, Zhang M, Iwanaga S, Yuda M, Tsuji M. 2017. A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII. Vaccine. 35(50):6990-7000.
  • Zhang M, Mandraju R, Rai U, Shiratsuchi T, Tsuji M. 2017. Monoclonal antibodies against Plasmodium falciparum circumsporozoite protein. Antibodies 6(3), 11; doi:10.3390/antib6030011
  • Nogueira RT, Sahi V, Huang J, Tsuji M. 2017. Human IgG repertoire of malaria antigen-immunized human immune system (HIS) mice. Immunol Lett. 188: 46-52.
  • Li X, Huang J, Kawamura A, Funakoshi R, Porcelli SA, Tsuji M. 2017. Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect. Vaccine. 35: 3171-3177.
  • Zhou J, Kaiser A, Ng C, Karcher R, McConnell T, Paczkowski P, Fernandez C, Zhang M, Mackay S, Tsuji M. 2017. CD8+ T-cell mediated anti-malaria protection induced by malaria vaccines; assessment of hepatic CD8+ T cells by SCBC assay. Hum Vaccin Immunother. 13: 1625-1629.
  • Steel RW, Sack BK, Tsuji M, Kappe SH. 2017. An opsonic phagocytosis assay for Plasmodium falciparum sporozoites. Clin Vaccine Immunol. 24. pii: e00445-16.
  • Li X, Huang J, Kaneko I, Zhang M, Iwanaga S, Yuda M, Tsuji M. 2017. A potent adjuvant effect of a CD1d-binding NKT cell ligand in human immune system mice. Expert Rev Vaccines 16:73-80
  • Li X, Huang J, Zhang M, Funakoshi R, Sheetij D, Spaccapelo R, Crisanti A, Nussenzweig V, Nussenzweig RS, Tsuji M. 2016. Human CD8+ T cells mediate protective immunity induced by a human malaria vaccine in human immune system mice. Vaccine 34:4501-6
  • Coelho-dos-Reis JG, Huang J, Tsao T, Pereira FV, Funakoshi R, Nakajima H, Sugiyama H, Tsuji M. 2016. Co-administration of a-GalCer analog and TLR4 agonist induces robust CD8+ T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells. Clin Immunol. 168: 6-15.
  • Zhang M, Kaneko I, Tsao T, Mitchell R, Nardin EH, Iwanaga S, Yuda M, Tsuji M. 2016. A highly infectious Plasmodium yoelii parasites, bearing Plasmodium falciparum circumsporozoite protein. Malaria J. 15: 201.
  • Sharma A, Wu W, Sung B, Huang J, Tsao T, Li X, Gomi R, Tsuji M, Worgall S. 2016. RSV Pulmonary Infection in Humanized Mice Induces Human Anti-RSV Immune Responses and Pathology. J Virol. 90: 5068-5074. Co-corresponding author.
  • Huang J, Li X, Coelho-dos-Reis JGA, Zhang M, Mitchell R, Tayar-Nogueira R, Tsao T, Noe AR, Ayala R, Sahi V, Gutierrez GM, Nussenzweig V, Wilson JM, Nardin EH, Nussenzweig RS, Tsuji M. 2015. Human immune system mice immunized with Plasmodium falciparum circumsporozoite protein induce protective human humoral immunity against malaria. J Immunol Methods 427:42-50.
  • Li X, Kawamura A, Andrews CD, Miller JL, Wu D, Tsao T, Zhang M, Oren D, Padte NN, Porcelli SA, Wong CH, Kappe SHI, Ho DD, Tsuji M. 2015. The co-localization of a CD1d-binding glycolipid with a radiation-attemuated sporozoites vaccine in LN-resident DCs for a robust adjuvant effect. J Immunol 195: 2710-2721.
  • Huang J, Tsao T, Zhang M, Tsuji M. 2014. Circumsporozoite Protein-Specific K(d)-Restricted CD8+ T Cells Mediate Protective Antimalaria Immunity in Sporozoite-Immunized MHC-I-K(d) Transgenic Mice. Mediators Inflamm. 2014: 728939.
  • Huang J, Li X, Coelho-dos-Reis JGA, Wilson JM, Tsuji M. 2014. An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8+ T cells in mice. PLOS ONE 9: e88205.
  • Padte NN, Boente-Carrera M, Andrews CD, McManus J, Grasperge BF, Gettie A, Coelho-dos-Reis JGA, Li X, Levenkova N, Wu D, Bruder JT, Sedegah M, Patterson N, Richie TL, Wong CH, Ho DD, Vasan S, Tsuji M. 2013 A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLOS ONE 8: e78407.
  • Coelho-dos-Reis JGA, Li X, Silveira ELV, Mandraju R, Velmurugan S, Chakravarty S, Suemizu H, Ito M, Sim BKL, Hoffman SL, Tsuji M. 2013.Plasmodium falciparum infection in “humanized liver” mice. MalariaWorld J. 4:9:1-4.
  • Kelly H, Mandraju R, Coelho-dos-Reis JGA, Tsuji M. 2013. Effects of HIV-induced CD1c and CD1d modulation and endogenous lipid presentation on CD1c-restricted T cell activation. BMC Immunol. 14: 4-14.
  • Huang J, Li X, Kohno K, Hatano M, Tokuhisa T, Murray PJ, Brocker T, Tsuji M. 2013. Generation of tissue-specific H-2Kd transgenic mice for the study of Kd-restricted malaria epitope-specific CD8+ T-cell responses in vivo. J. Immunol. Methods 387: 254-261.
  • Avci FY, Li X, Tsuji M#, Kasper DL#. 2012. Isolation of carbohydrate specific CD4+ T cell clones from two model glycoconjugate vaccines. Nat. Protoc. 7: 2180-2192 #Co-corresponding Author.
  • Li X, Polacino P, Garcia-Navarro R, Hu S-L, Tsuji M. 2012. Peripheral blood invariant natural killer T cells of pig-tailed macaques. PLoS ONE 7: e48166.
  • Rai U, Huang J, Shiratsuchi T, Li X, Mishra S, Tsuji M. 2012. A new method to determine antigen-specific CD8+ T cell activity in vivo by hydrodynamic injection. Biomolecules 2: 23-33.
  • Shiratsuchi T, Kraus A, Worgall S, Tsuji M. 2010. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents pre-existing immunity to adenovirus in mice. J. Clin. Inv. 120: 3688-3701.
  • Li X, Fujio M, Imamura M, Wu D,Vasan S, Wong C-H, Ho DD, Tsuji M. 2010. Design of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc. Natl. Acad. Sci. USA.
  • Schmieg J, Yang G, Franck RW, Tsuji M. 2010. A multifactorial mechanism in the superior anti-malarial activity of a-C-GalCer. J. Biomed. Biotech.
  • Horowitz A, Li X, Poles MA, Tsuji M. 2009. Quantifying cytokine production by epitope-specific, HLA-restricted CD8+ T cells after stimulation by immobilized HLA-A2:Ig dimeric proteins. Scan. J. Immunol. 70: 415-422.
  • Li X, Shiratsuchi T, Chen G, Franck RW, Tsuji M. 2009. Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine iNKT cells. J. Immunol. 183: 4415-4421.
  • Li X, Chen G, Garcia-Navarro R, Franck RW, Tsuji M. 2009. Identification of C-glycoside analogues that display a potent activity against human NKT cells. Immunology 127: 216-225.
  • Shiratsuchi T, Schneck J, Kawamura A, Tsuji M. 2009. Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. J. Immunol. Methods 345: 49-59.
  • Huang Y, Chen A, Li X, Chen Z, Zhang W, Song Y, Gurner D, Gardiner D, Basu S, Ho DD, Tsuji M. 2008. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand α-galactosylceramide. Vaccine 26: 1807-1816.
  • Vasan S, Poles MA, Horowitz A, Siladji EE, Markowitz M, Tsuji M. 2007. Percentage and function of NKT cells, a potential anti-HIV effector cell, are preserved by beginning HAART during acute and early HIV-1 Infection. Int. Immunol. 19: 943-951.
  • Ophorst OJAE, Radosevic K, Havenga MJE, Pau MG, Holterman L, Berkhout B, Goudsmit J, Tsuji M. 2006. Recombinant human adenovirus serotype 35-based malaria vaccine: Immunogenicity and protection against Plasmodium yoelii in mice. Infect. Immun. 74: 313-320.
  • Schmieg J, Yang G, Franck RW, Van Rooijen N, Tsuji M. 2005. Glycolipid-presentation to natural killer T cells differs in an organ-dependent fashion. Proc. Natl. Acad. Sci. USA. 102: 1127-1132.
  • Schmieg J, Yang G, Franck RW, Tsuji M. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand a-galactosylceramide. J. Exp. Med. 198: 1631-1641.
  • Bruna-Romero O, Schmieg J, Del Val M, Buschle M, Tsuji M. 2003. The dendritic cell-specific chemokine DC-CK1 enhances protective cell-mediated immunity to murine malaria. J. Immunol. 170: 3195-3203.
  • Gonzalez-Aseguinolaza G, Van Kear L, Bergmann CC, Wilson JM, Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y, Tsuji M. 2002. The natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195: 617-624.
  • Fernandez JA, Rodrigues EG, Tsuji M. 2000. Multifactorial protective mechanisms to limit viral replication in the lung of mice during primary murine cytomegalovirus infection. Viral. Immunol. 13: 287-295.
  • Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, Hong S, Bruna-Romero O, Nakayama T, Taniguchi M, Bendelac A, Van Kaer L, Koezuka Y, Tsuji, M. 2000. α-GalCer-activated Vα14 natural killer T cells mediate protection against murine malaria. Proc. Natl. Acad. Sci. USA. 97: 8461-8466.
  • Molano A, Chiu Y-H, Nosseir S, Bendelac A, Tsuji M. 2000. Cutting Edge: The IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: Exploring the role of GPIs in NKT cell activation and antimalarial responses. J. Immunol. 164: 5005-5009.
  • Rodrigues EG, Claassen J, Lee S, Wilson JM, Nussenzweig RS, Tsuji M. 2000. Interferon-gamma Independent CD8+ T cell-mediated protective anti-malaria immunity induced by recombinant adenovirus. Parasite Immunol. 22: 157-160.
  • Gonzalez-Aseguinolaza G, de Oliveira C, Koezuka Y, Nussenzweig RS, Van Kaer L, Bendelac A, Tsuji M. 1999. Protective role of NKT cells against liver stages of malaria infection in mice. Am. J. Trop. Med. Hyg. 61: 341
  • Fernandez JA, Zavala F, Tsuji M. 1999. Phenotypic and functional characterization of CD8+ T cell clones specific for a mouse cytomegalovirus epitope. Virology 155: 40-49.
  • Rodrigues EG, Zavala F, Nussenzweig RS, Wilson JM, Tsuji M. 1998. Efficient induction of protective anti-malaria immunity by recombinant adenovirus. Vaccine 16: 1812-17.
  • Rodrigues EG, Zavala F, Eichinger D, Wilson JM, Tsuji M. 1997. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J. Immunol. 158: 1268-74.